SynthesisEuropean radiology2026
Prognostic value of late gadolinium enhancement on cardiac magnetic resonance imaging for non-sustained ventricular tachycardia and sudden cardiac death in hypertrophic cardiomyopathy: a meta-analysis.
Synthesis in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveNon-sustained ventricular tachycardia (NSVT) is an independent predictor of sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM). This meta-analysis evaluates the prognostic value of late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) for predicting NSVT and its association with SCD in HCM. MATERIALS AND
methodsWe screened electronic databases for studies evaluating the prognostic value of LGE in predicting NSVT and SCD in HCM patients. A random-effects model estimated pooled sensitivity, specificity, accuracy, predictive values, and likelihood ratios for NSVT prediction. Association between LGE extent and NSVT incidence was analyzed using weighted mean differences (WMDs), while pooled odds ratios (ORs) with 95% CIs were calculated to assess LGE's association with SCD.
resultsAmong 20 studies, LGE showed a pooled sensitivity, specificity, and accuracy of 91.33% (95% CI: 88.81-93.86), 37.45% (95% CI: 31.60-43.31), and 52.86% (95% CI: 45.73-59.98), respectively, for NSVT prediction. Positive and negative likelihood ratios and predictive values were, 1.40 and 0.23, and 36.35% and 92.03%, respectively. Patients with NSVT had a significantly greater LGE extent than those without (WMD: 5.95%, 95% CI: 3.08-8.81, p < 0.0001). NSVT prevalence was 28.73% (95% CI: 20.91-36.54). Additionally, LGE presence and SCD were significantly associated (OR 3.64, 95% CI: 2.36-5.61, p < 0.00001).
conclusionLGE on CMR shows high sensitivity but limited specificity and accuracy for NSVT prediction. Moreover, LGE presence was significantly associated with SCD, and NSVT patients had greater LGE extent. Nonetheless, variability in predictive values and likelihood ratios underscores the need to combine LGE with other imaging biomarkers. KEY POINTS: Question Can LGE on CMR predict NSVT and SCD in HCM patients? Findings LGE demonstrated high sensitivity but limited specificity for NSVT prediction. Moreover, LGE presence was significantly associated with SCD, and NSVT patients had greater LGE extent. Clinical relevance LGE on CMR is a valuable marker for NSVT prediction and SCD in HCM patients, but it is not widely integrated into clinical practice. Our study highlights the need to integrate LGE with other imaging biomarkers for improved risk stratification.
Indexed as
Identifiers
40836019What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.